At Torrance Memorial Physician Network Cancer Care we are committed to
the advancement of effective new cancer therapy.
The following clinical trials are available at Torrance Memorial Physician
Network Cancer Care in coordination with the
TRIO-US / Clinical Trials Network. This is a unique opportunity for patients in the South Bay to receive
advanced research treatments previously restricted to university cancer
centers. TRIO-US / Clinical Trials Network affiliated program auspiciously
places Torrance Memorial Physician Network patients into the promising
new era of cancer treatment research. All patients enrolled in these trials
are treated at our
infusion center in Redondo Beach.
The following studies are subject to change by TRIO-US / Clinical Trials
Network and the participating pharmaceutical companies and may not be
continually or currently open. Enrollment and participation in these studies
is voluntary and patients can choose to withdraw at any time and for any
reason. All experimental study drugs are provided at no charge.
Each study has precise entry criteria for enrollment because the researchers
are attempting to answer a specific treatment question, within a specific
clinical parameter, so not all interested patients will be eligible to
participate. It is notable that most of the studies involve drugs that
are pathway-specific or targeted, which has been a major trend in cancer
research over the past decade as the molecular secrets of cancer growth
are revealed.
| Disease |
Title |
Summary |
Status |
Investigator |
| Breast Cancer |
neoMonarch Lilly JPBY Breast Cancer |
A preoperative endocrine study for postmenopausal hormone receptor positive
breast cancer evaluating the effectiveness of adding a CKD4/6 inhibitor
to standard anastrozole (Arimidex). For 4 months before surgery. CKD4/6
inhibitors are active in increasing benefits of aromatase inhibitors in
stage 4 breast cancer. Aromatase inhibitors given before surgery result
in smaller cancers and lower mastectomy rates. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
PUMA NER-6201 Breast Cancer |
Neritinib is a experimental 2nd generation oral HER2 targeting drug that
has reduced relapsed rate after HER2 based chemotherapy in early breast
cancer. Patients receive neritinib for one year to monitor tolerance and
side effects. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
Novartis CLEE011E2301 (MONALEESA-7) Breast Cancer |
A Phase 3 randomized study of LEE011, a new CDK4/6 inhibitor with tamoxifen
or an aromatase inhibitor in combination with goserelin in the treatment
of premenopausal hormone receptor positive, HER2-negative, advanced breast
cancer. This study evaluates the effectiveness of an experimental targeted
drug in improving the endocrine treatment. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
TRIO-US B-10 Breast Cancer |
A phase 2 randomized trial of MuGard for prevention and treatment of mouthsores
in women with hormone receptor positive breast cancer receiving treatment
with everolimus-endocrine therapy. Afinitor is often used in combination
with Aromasin in stage 4 breast cancer. Patients often have uncomfortable
mouth sores. This study assesses Mugard in reducing mucositis. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
GNE GO29227 (LOTUS) Breast Cancer |
A randomized Phase 2 multicenter study of ipatasertib (GDC-0068), an inhibitor
of AKT, in combination with paclitaxel as first-line treatment for patients
with metastatic triple-negative breast cancer. Triple negative breast
cancers are ER, PR and HER2 negative. The AKT pathway is targeted in this study. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
Clovis CO-3810-025 (LUCY) Breast Cancer |
A Phase 2 multicenter study of oral lucitanib in patients with FGF aberrant
metastatic breast cancer. About 15% of breast cancers have the FGFR pathway.
This study uses an oral targeted drug to attack that pathway. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
Biomarin BMN 673-301/201 (EMBRACA) Breast Cancer |
A Phase 3 randomized multi-center study of BMN 673 versus Physician’s
Choice in BRCA positive with locally advanced or metastatic breast cancer,
who have received no more than 2 prior chemotherapy regimens. BMN 673
is an oral PARP inhibitor and PARP pathway is important in BRCA related
breast cancers. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
TRIO 020 Breast Cancer
|
A randomized phase 2 trial of letrozole plus afatinib versus letrozole
alone in postmenopausal hormone receptor positive, HER2 negative patients
with metastatic disease with low ER expression. Afatinib is approved to
treat EGFR positive lung cancer and has activity in breast cancer. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
Merrimack MM-302-02-02-03 Breast Cancer |
A randomized multicenter study of MM-302 plus trastuzumab vs. standard
chemotherapy plus trastuzumab in anthracycline naïve patients with
locally advanced/metastatic HER2-Positive breast cancer. MM-302 is a new
encapsulated anthracycline that targets the HER2 protein. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
TRIO-US B-09 Breast Cancer |
Phase 1b/2 trial evaluating the combination of lapatinib, everolimus and
capecitabine for the treatment of patients with HER2-positive metastatic
breast cancer with CNS progression after trastuzumab. This study evaluates
the effective of using 3 oral drugs in treating HER2 positive breast cancer
with brain involvement. |
Open/Active |
David Chan, M.D. |
| Breast Cancer |
PUMA NER 1301 (NALA) Breast Cancer |
A study of neratinib plus capecitabine versus lapatinib plus capecitabine
in patients with HER2-positive metastatic breast cancer who have received
two or more prior HER2-directed regimens in the metastatic setting. This
study evaluates 2 oral combinations targeting HER2 in stage 4 breast cancer. |
Open/Active |
David Chan, M.D. |
| GI Cancer |
Lilly I4T-MC-JVCU (RAINFALL) Gastric Cancer |
A randomized Phase 3 Study of capecitabine and cisplatin with or without
ramucirumab in first-line therapy of patients with metastatic gastric/GE
junction adenocarcinoma. This study evaluates a 2nd generation angiogenesis
inhibitor in combination with standard chemotherapy for stage 4 cancers
of the stomach and lower esophagus. |
Open/Active |
Hugo Hool, M.D. |
| GI Cancer |
Merrimack 141-07-02-02 (CARRIE) Pancreatic Cancer |
A randomized Phase 2 Study of MM-141 used in combination with Abraxane
and Gemzar in 1st line metastatic pancreatic cancer. The study drug is
a bi-specific antibody attacking the IGF pathway. |
Open/Active |
Hugo Hool, M.D. |
| GI Cancer |
Incyte INCB 18424-362 (JANUS1) Pancreatic Cancer |
A randomized Phase 3 Study of the JAK1/2 Inhibitor, ruxolitinib in combination
with capecitabine in advanced or metastatic cancer of the pancreas who
have already had one round of chemotherapy. This 2nd line regimen uses
all oral drugs. |
Open/Active |
Hugo Hool, M.D. |
| Lung Cancer |
AstraZeneca D419A (MYSTIC) NSCLC |
A phase 3 trial comparing standard platinum based chemotherapy with the
addition of single or double immunotherapies with experimental checkpoint
inhibitors. This is a key study in moving checkpoint inhibitors earlier
in the treatment cycle. |
Open/Active |
Thomas Lowe, M.D. |
| Lung Cancer |
Clovis CO-1686-020 (TIGER 3) NSCLC |
A Phase 3 multicenter randomized Study of oral CO-1686 versus single chemotherapy
in patients with mutant EGFR non-small cell lung cancer (NSCLC) after
previous treatment with EGFR-directed tyrosine kinase inhibitor (TKI)
and a platinum doublet chemotherapy. This study evaluates a next generation
oral inhibitor of EGFR. |
Open/Active |
Thomas Lowe, M.D. |
| Lung Cancer |
Lilly I3Y-MC-JPBK (JUNIPER) NSCLC |
A Randomized Phase 3 Study of abemaciclib versus Erlotinib in patients
with Stage IV NSCLC with a detectable KRAS Mutation who have progressed
after platinum-based chemotherapy. The study drug is a new CDK4/6 inhibitor. |
Open/Active |
Thomas Lowe, M.D. |
| Head and Neck Cancer |
AstraZeneca D4193 (HAWK) |
This is an immunotherapy trial. MED1476 is an experimental antibody checkpoint
inhibitor that results in immune destruction across a wide range of cancers.
Patients who have relapsed after previous radiation and chemotherapy are eligible. |
Open/Active |
Thomas Lowe, M.D. |
| Head and Neck Cancer |
AstraZeneca D4193 (Eagle 02) |
This study evaluates two checkpoint inhibitors that promote the immune
system to eradicate cancer. MED1476 alone, or paired with tremelimumab
is compared with best standard chemotherapy. |
Open/Active |
Thomas Lowe, M.D. |
| Head and Neck Cancer |
AstraZeneca D4193 (CONDOR) |
This is an immunotherapy trial. The checkpoint inhibitor MED1476, the checkpoint
inhibitor tremelimumab are given singly or in combination in patients
who have progressed after standard chemotherapy. |
Open/Active |
Thomas Lowe, M.D. |
| Lymphoma Cancer |
"Trio" AstraZeneca D419CC00002 |
A Phase 3, randomized stud of GS-1101 (CAL-101) in combination with rituximab
for previously treated Indolent Non-Hodgkin Lymphoma. This study tests
an oral drug combined with an antibody in patients with low grade lymphoma. |
Open/Active |
Hugo Hool, M.D. |
| Bladder Cancer |
Lilly I4T-MC-JVDC Bladder |
A Phase 3, randomized study of ramucirumab plus docetaxel in patients with
locally advanced or unresectable or metastatic urothelial carcinoma who
progressed on or after platinum-based combination chemotherapy. |
Open/Active |
Thomas Lowe, M.D. |
The following clinical trials are available at Torrance Memorial Physician
Network Cancer Care and are not in coordination with the
TRIO-US / Clinical Trials Network.
| Disease |
Title |
Summary |
Status |
Investigator |
| All Solid Tumors |
LexentBio LB-1985106 |
Employ genomic detection methodologies to measure the relative amount of
tumor-derived nucleic acids in the blood of patients diagnosed with advanced
malignancy who are either commencing, currently undergoing or have completed
treatment. |
Open/Active |
David Chan M.D. |
| Lung |
“Vision” Quintiles MS200095-0022 |
Phase II single-arm trial to investigate Tepotinib in advanced (stage IIIB/IV)
non-small cell lung cancer with MET exon 14 (METex14) skipping alterations
(SCREENING SITE) |
Open/Active |
Andrew Horodner M.D. |
| Breast mBC |
"Contessa" Odonate ODO-TE-B301 |
This is a multinational, multicenter, randomized, open-label, parallel
group Phase 3 study. The primary objective is to compare the efficacy
of tesetaxel plus a reduced dose of capecitabine versus the approved dose
of capecitabine alone based on PFS, as assessed by an Independent Radiologic
Review Committee (IRC), in patients with HER2 negative, HR positive, LA/MBC
previously treated with a taxane in the neoadjuvant or adjuvant setting. |
Open/Active |
Swati Sikaria, MD |
| Colon Colorectal |
"Nova" Clinical Genomics CG001 |
Evaluation of the performance of the Clinical Genomics Colvera blood test
in the detection of disease recurrence in patients diagnosed with Colorectal
cancer. Liquid biopsy collection. |
Open/Active |
David Chan, M.D. |
| Colon Colorectal |
"Pascal" Clinical Genomics CG013 |
Evaluation of the Performance and Sensitivity of the Clinical Genomics
Colvera Test in Predicting Recurrence of Colorectal Cancer (Paired Analysis
of Sensitivity for Colorectal Cancer using COLVERA : PASCAL) Liquid biopsy
collection. |
Open/Active |
David Chan, M.D. |
| Disease |
Title |
Summary |
Status |
Investigator |
| Breast HR+ |
"monarchE" Lilly I3Y-MC-JPCF |
The purpose of this study is to evaluate the safety and efficacy of the
study drug abemaciclib in participants with high risk, node positive,
early stage, hormone receptor positive (HR+), human epidermal receptor
2 negative (HER2-), breast cancer. |
Open/Active |
David Chan, M.D. |
| Breast DCIS |
"Comet" Alliance Foundation Trials, Inc AFT-25 |
This study looks at the risks and benefits of active surveillance (AS)
compared to guideline concordant care (GCC) in the setting of a pragmatic
prospective randomized trial for low risk DCIS. Our overarching hypothesis
is that management of low-risk Ductal Carcinoma in Situ (DCIS) using an
AS approach does not yield inferior cancer or quality of life outcomes
compared to GCC. |
Open/Active |
Swati Sikaria, MD |
| Liver Hepatocellular |
"Himalaya" AstraZeneca D419CC00002 |
This is a randomized, open-label, multi-center, global, Phase III study
to assess the efficacy and safety of durvalumab plus tremelimumab combination
therapy and durvalumab monotherapy versus sorafenib in the treatment of
patients with no prior systemic therapy for unresectable HCC. The patients
cannot be eligible for locoregional therapy. |
Open/Active |
Syed Jilani, MD |
| Kidney Renal Cell Carcinoma |
"Cantata" Calithera Biosciences, Inc CX-839-008 |
This study is a randomized Phase 2 evaluation of CB-839 in combination
with cabozantinib versus placebo with cabozantinib in Renal Cell Carcinoma
patients with at least one and not more than 2 prior therapies in the
advanced or metastatic setting. |
Open/Active |
Vanessa Dickey, MD |
| Tapur |
“Tapur” Sponsor: ASCO NCT02693535 |
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is
a non-randomized clinical trial that aims to describe the safety and efficacy
of commercially available, targeted anticancer drugs prescribed for treatment
of patients with advanced cancer that has a potentially actionable genomic
variant. TAPUR will study Food and Drug Administration (FDA)-approved
targeted therapies that are contributed by collaborating pharmaceutical
companies, catalogue the choice of molecular profiling test by clinical
oncologists and develop hypotheses for additional clinical trials.
Treats:
- CML
- Leukemia
- NHL- Non-Hodgkin’s Lymphoma
- MM- Multiple Myeloma
- Solid Tumors
More Info Available:
WWW.CLINICALTRIALS.GOV
NCT02693535
www.Tapur.org
|
Open/Active |
Swati Sikaria, MD |